AFPBharat Biotech on Tuesday said it will continue the steady supply of its COVID-19 vaccine Covaxin, adding the jab has been directly supplied to 18 states since May 1.
The states include Andhra Pradesh, Delhi, Bihar, Gujarat, Haryana, Uttar Pradesh and West Bengal, the Hyderabad-based firm added.
"COVAXIN has been directly supplied to 18 states since May 1st. Unflinching in our efforts, we will continue the steady supply of our #vaccine," Bharat Biotech said in a tweet.
The company is supplying its vaccine to Andhra Pradesh, Assam, Bihar, Chhattisgarh, Delhi, Gujarat, Haryana, Jammu & Kashmir, Jharkhand, Karnataka, Madhya Pradesh, Maharashtra, Odisha, Tamil Nadu, Tripura, Telangana, Uttar Pradesh and West Bengal.
Bharat Biotech has commenced direct supply of Covaxin with effect from May 1 to several states based on the allocations received by the central government, the company's Joint Managing Director Suchitra Ella had earlier said.
On April 29, Bharat Biotech had announced a cut in the price of Covaxin for states to Rs 400 per dose from the earlier Rs 600.
This followed widespread criticism of its pricing policy as it sold Covaxin to the central government at Rs 150 per dose.
India has expanded its COVID-19 vaccination drive by allowing its large 18-plus population to get inoculated from May 1.
The states include Andhra Pradesh, Delhi, Bihar, Gujarat, Haryana, Uttar Pradesh and West Bengal, the Hyderabad-based firm added.
"COVAXIN has been directly supplied to 18 states since May 1st. Unflinching in our efforts, we will continue the steady supply of our #vaccine," Bharat Biotech said in a tweet.
The company is supplying its vaccine to Andhra Pradesh, Assam, Bihar, Chhattisgarh, Delhi, Gujarat, Haryana, Jammu & Kashmir, Jharkhand, Karnataka, Madhya Pradesh, Maharashtra, Odisha, Tamil Nadu, Tripura, Telangana, Uttar Pradesh and West Bengal.
Bharat Biotech has commenced direct supply of Covaxin with effect from May 1 to several states based on the allocations received by the central government, the company's Joint Managing Director Suchitra Ella had earlier said.
On April 29, Bharat Biotech had announced a cut in the price of Covaxin for states to Rs 400 per dose from the earlier Rs 600.
This followed widespread criticism of its pricing policy as it sold Covaxin to the central government at Rs 150 per dose.
India has expanded its COVID-19 vaccination drive by allowing its large 18-plus population to get inoculated from May 1.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.